Is erythropoietin a potential therapy for amyotrophic lateral sclerosis?

Experimental Neurology

Volumn 206, Issue 1, 2007, Pages 11-15

  Butsch, Patrick O ^a   Cudkowicz, Merit E ^a  

^a Neurology Clinical Trial Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; ARYLDIALKYLPHOSPHATASE; COPPER ZINC SUPEROXIDE DISMUTASE; ERYTHROPOIETIN; ERYTHROPOIETIN BETA; HELICASE; RILUZOLE; RNA HELICASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOSOMAL DOMINANT INHERITANCE; CYTOSKELETON; CYTOSOL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA POLYMORPHISM; DRUG EFFECT; DRUG EFFICACY; EXCITOTOXICITY; GENE MUTATION; HUMAN; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN AGGREGATION;

EID: 34250612703     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.04.001     Document Type: Note

References (63)

1. Al-Chalabi A., Enayat Z., Bakker M., Sham P., Ball D., CE S., Lloyd C., Powell J., and Leigh P. Association of apolipoprotein E epsilon 4 allele with bulbar-onset motor neuron disease. Lancet 347 (1996) 159-160
2. Al-Chalabi A., Hansen V.K., Simpson C.L., Xi J., Hosler B.A., Powell J.F., McKenna-Yasek D., Shaw C.E., Leigh P.N., and Brown Jr. R.H. Variants in the ALS2 gene are not associated with sporadic amyotrophic lateral sclerosis. Neurogenetics 4 (2003) 221-222
3. Beleslin-Cokic B.B., Cokic V.P., Yu X., Weksler B.B., Schechter A.N., and Noguchi C.T. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 104 (2004) 2073-2080
4. Bennett C.L., Luminari S., Nissenson A.R., Tallman M.S., Klinge S.A., McWilliams N., McKoy J.M., Kim B., Lyons E.A., Trifilio S.M., Raisch D.W., Evens A.M., Kuzel T.M., Schumock G.T., Belknap S.M., Locatelli F., Rossert J., and Casadevall N. Pure red-cell aplasia and epoetin therapy. New England Journal of Medicine 351 (2004) 1403-1408
5. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group. New England Journal of Medicine 330 (1994) 585-591
6. Brettschneider J., Widl K., Ehrenreich H., Riepe M., and Tumani H. Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases. Neuroscience Letters 404 (2006) 347-351
7. Brines M., and Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nature Reviews. Neuroscience 6 (2005) 484-494
8. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., Itri L.M., and Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proceedings of the National Academy of Sciences 97 (2000) 10526-10531
9. Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., Latini R., Xie Q.-w., Smart J., Su-Rick C.-j., Pobre E., Diaz D., Gomez D., Hand C., Coleman T., and Cerami A. Erythropoietin mediates tissue protection through an erythropoietin and common {beta}-subunit heteroreceptor. Proceedings of the National Academy of Sciences 101 (2004) 14907-14912
10. Bruijn L., Becher M., Lee M., Anderson K., Jenkins N., Copeland N., Sisodia S., Rothstein J., Borchelt D., Price D., and Cleveland D. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 18 (1997) 327-338
11. Chen Y.-Z., Bennett C.L., Huynh H.M., Blair I.P., Puls I., Joy Irobi I.D., Abel A., Kennerson M.L., Rabin B.A., Nicholson G.A., Auer-Grumbach M., Wagner K., De Jonghe P., Griffin J.W., Fischbeck K.H., Timmerman V., Cornblath D.R., and Chance P.F. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). American Journal of Human Genetics 74 (2004) 1128-1135
12. Cleveland D.W., and Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nature Reviews. Neuroscience 2 (2001) 806-819
13. Cudkowicz M., McKenna-Yasek D., Sapp P., Chin W., Geller B., Hayden D., Schoenfeld D., BA H., Horvitz H., and Brown R. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Annals of Neurology 41 (1997) 210-221
14. Cudkowicz M., Pastusza K., Sapp P., Mathews R., Leahy J., Pasinelli P., Francis J., Jiang D., Andersen J., and Brown R. Survival in transgenic ALS mice does not vary with CNS glutathione peroxidase activity. Neurology 59 (2002) 729-734
15. Cudkowicz M., Shefner J., Schoenfeld D., Brown R.J., Johnson H., Qureshi M., Jacobs M., Rothstein J., Appel S., Pascuzzi R., Heiman-Patterson T., Donofrio P., David W., Russell J., Tandan R., Pioro E., Felice K., Rosenfeld J., Mandler R., Sachs G., Bradley W., Raynor E., Baquis G., Belsh J., Novella S., Goldstein J., Hulihan J., and NEALS. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 61 (2003) 456-464
16. Cudkowicz M., Shefner J., Schoenfeld D., Zhang H., Andreasson K., Rothstein J., Drachman D., and NEALS. Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology 60 (2006) 22-31
17. Dal Canto M.C., and Gurney M.E. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Research 676 (1995) 25-40
18. De Cree C. Sex steroid metabolism and menstrual irregularities in the exercising female. A review. Sports Medicine 25 (1998) 369-406
19. Desnuelle C., Dib M., Garrel C., and Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders 2 (2001) 9-18
20. DiBernardo A.B., and Cudkowicz M.E. Translating preclinical insights into effective human trials in ALS. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1762 (2006) 1139-1149
21. Erbayraktar S., Grasso G., Sfacteria A., Xie Q.-w., Coleman T., Kreilgaard M., Torup L., Sager T., Erbayraktar Z., Gokmen N., Yilmaz O., Ghezzi P., Villa P., Fratelli M., Casagrande S., Leist M., Helboe L., Gerwien J., Christensen S., Geist M.A., Pedersen L.O., Cerami-Hand C., Wuerth J.-P., Cerami A., and Brines M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proceedings of the National Academy of Sciences 100 (2003) 6741-6746
22. Giess R., Goetz R., Schrank B., Ochs G., Sendtner M., and Toyka K. Potential implications of a ciliary neurotrophic factor gene mutation in a German population of patients with motor neuron disease. Muscle and Nerve 21 (1998) 236-238
23. Greenway M.J., Alexander M.D., Ennis S., Traynor B.J., Corr B., Frost E., Green A., and Hardiman O. A novel candidate region for ALS on chromosome 14q11.2. Neurology 63 (2004) 1936-1938
24. Greenway M., Andersen P., Russ C., Ennis S., Cashman S., Donaghy C., Patterson V., Swingler R., Kieran D., Prehn J., Morrison K., Green A., Acharya K.R., Brown Jr. R.H., and Hardiman O. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nature Genetics 38 (2006) 411-413
25. Grignaschi G., Zennaro E., Tortarolo M., Calvaresi N., and Bendotti C. Erythropoietin does not preserve motor neurons in a mouse model of familial ALS. Amyotrophic Lateral Sclerosis 8 (2007) 31-35
26. Grunfeld J.F., Barhum Y., Blondheim N., Rabey J.-M., Melamed E., and Offen D. Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Experimental Neurology 204 (2007) 260-263
27. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.-X., Chen W., Zhai P., Sufit R.L., and Siddique T. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
28. Hadano S., Hand C., Osuga H., Yanagisawa Y., Otomo A., Devon R., Miyamoto N., Showguchi-Miyata J., Okada Y., Singaraja R., Figlewicz D., Kwiatkowski T., Hosler B., Sagie T., Skaung J., Nasir J., Brown R.J., Scherer S., Rouleau G., Hayden M., and Ikeda J. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nature Genetics 29 (2001) 166-173
29. Hafezparast M., Ahmad-Annuar A., Hummerich H., Shah P., Ford M., Baker C., Bowen S., Martin J.E., and Fisher E.M. Paradigms for the identification of new genes in motor neuron degeneration. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders 4 (2003) 249-257
30. Hirtz D., Thurman D.J., Gwinn-Hardy K., Mohamed M., Chaudhuri A.R., and Zalutsky R. How common are the "common" neurologic disorders?. Neurology 68 (2007) 326-337
31. Howland D., Liu J., She Y., Goad B., Maragakis N., Kim B., Erickson J., Kulik J., DeVito L., Psaltis G., DeGennaro L., Cleveland D., and Rothstein J. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proceedings of the National Academy of Sciences 99 (2002) 1604-1609
32. Kaspar B.K., Llado J., Sherkat N., Rothstein J.D., and Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301 (2003) 839-842
33. Kawakami M., Iwasaki S., Sato K., and Takahashi M. Erythropoietin inhibits calcium-induced neurotransmitter release from clonal neuronal cells. Biochemical and Biophysical Research Communications 279 (2000) 293-297
34. Kurtzke J., and Kurland L. The epidemiology of neurologic disease. In: Joynt R. (Ed). Clinical Neurology (1989), J.B. Lippincot, Philadelphia 1-43
35. Lacomblez L., Bensimon G., Leigh P., Guillet P., and Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347 (1996) 1425-1431
36. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S., Wyns S., Thijs V., Andersson J., van Marion I., Al-Chalabi A., Bornes S., Musson R., Hansen V., Beckman L., Adolfsson R., Pall H., Prats H., Vermeire S., Rutgeerts P., Katayama S., Awata T., Leigh N., Lang-Lazdunski L., Dewerchin M., Shaw C., Moons L., Vlietinck R., Morrison K., Robberecht W., Van Broeckhoven C., Collen D., Andersen P., and Carmeliet P. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nature Genetics 34 (2003) 383-394
37. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., Kallunki P., Larsen A.K., Helboe L., Christensen S., Pedersen L.O., Nielsen M., Torup L., Sager T., Sfacteria A., Erbayraktar S., Erbayraktar Z., Gokmen N., Yilmaz O., Cerami-Hand C., Xie Q.-W., Coleman T., Cerami A., and Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 (2004) 239-242
38. Mennini T., De Paola M., Bigini P., Mastrotto C., Fumagalli E., Barbera S., Mengozzi M., Viviani B., Corsini E., Marinovich M., Torup L., Van Beek J., Leist M., Brines M., Cerami A., and Ghezzi P. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Molecular Medicine 12 (2006) 153-160
39. Morishita E., Masuda S., Nagao M., Yasuda Y., and Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76 (1996) 105-116
40. Mui S., Rebeck G., McKenna-Yasek D., Hyman B., and Brown R. Apolipoprotein E E4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. Annals of Neurology 38 (1995) 460-463
41. Nagai M., Aoki M., Miyoshi I., Kato M., Pasinelli P., Kasai N., Brown Jr. R.H., and Itoyama Y. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. Journal of Neuroscience 21 (2001) 9246-9254
42. Nishimura A.L., M.-N.M., Silva H.C., Richieri-Costa A., Middleton S., Cascio D., Kok F., Oliveira J.R., Gillingwater T., Webb J., Skehel P., and Zatz M. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. American Journal of Human Genetics 75 (2004) 822-831
43. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Dorpe J.V., Hellings P., Gorselink M., Heymans S., Theilmeier G., Dewerchin M., Laudenbach V., Vermylen P., Raat H., Acker T., Vleminckx V., Bosch L.V.D., Cashman N., Fujisawa H., Drost M.R., Sciot R., Bruyninckx F., Hicklin D.J., Ince C., Gressens P., Lupu F., Plate K.H., Robberecht W., Herbert J.-M., Collen D., and Carmeliet P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nature Genetics 28 (2001) 131-138
44. Orrell R., King A., Lane R., and de Belleroche J. Investigation of a null mutation of the CNTF gene in familial amyotrophic lateral sclerosis. Journal of the Neurological Sciences 132 (1995) 126-128
45. Pasinelli P., Borchelt D., Houseweart M., Cleveland D., and Brown R. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proceedings of the National Academy of Sciences 95 (1998) 15763-15768
46. Pasinelli P., Houseweart M., Brown R., and Cleveland D. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu/Zn superoxide dismutase mediated familial amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences 97 (2000) 13901-13906
47. Puls I., Jonnakuty C., LaMonte B., Holzbaur E., Tokito M., Mann E., Floeter M., Bidus K., Drayna D., Oh S., Brown R., Ludlow C., and Fischbeck K. Mutant dynactin in motor neuron disease. Nature Genetics 33 (2003) 455-456
48. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.-X., Rahmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S.M., Berger R., Tanzi R.E., Halperin J.J., Herzfeldt B., Van den Bergh R., Hung W.-Y., Bird T., Deng G., Mulder D.W., Smyth C., Laing N.G., Soriano E., Pericak-Vance M., Haines J., Rouleau G.A., Gusella G.S., Horvitz H.R., and Brown Jr. R.H. Mutations in Cu/Zn superoxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
49. Rothstein J.D. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Annals of Neurology 53 (2003) 423-426
50. Rowland L.P. Ten central themes in a decade of ALS research. In: Rowland L.P. (Ed). Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases (1992), Raven Press 3-23
51. Saeed M., Siddique N., Hung W.Y., Usacheva E., Liu E., Sufit R.L., Heller S.L., Haines J.L., Pericak-Vance M., and Siddique T. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology 67 (2006) 771-776
52. Sakanaka M., Wen T.-C., Matsuda S., Masuda S., Morishita E., Nagao M., and Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proceedings of the National Academy of Sciences 95 (1998) 4635-4640
53. Shefner J.M., Cudkowicz M.E., Schoenfeld D., Conrad T., Taft J., Chilton M., Urbinelli L., Qureshi M., Zhang H., Pestronk A., Caress J., Donofrio P., Sorenson E., Bradley W., Lomen-Hoerth C., Pioro E., Rezania K., Ross M., Pascuzzi R., Heiman-Patterson T., Tandan R., Mitsumoto H., Rothstein J., Smith-Palmer T., MacDonald D., Burke D., and NEALS. A clinical trial of creatine in amyotrophic lateral sclerosis. Neurology 63 (2004) 1656-1661
54. Singer C.A., Figueroa-Masot X.A., Batchelor R.H., and Dorsa D.M. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. Journal of Neuroscience 19 (1999) 2455-2463
55. Siren A.-L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., Keenan S., Gleiter C., Pasquali C., Capobianco A., Mennini T., Heumann R., Cerami A., Ehrenreich H., and Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proceedings of the National Academy of Sciences 98 (2001) 4044-4049
56. Slowik A., Tomik B., Wolkow P.P., Partyka D., Turaj W., Malecki M.T., Pera J., Dziedzic T., Szczudlik A., and Figlewicz D.A. Paraoxonase gene polymorphisms and sporadic ALS. Neurology 67 (2006) 766-770
57. Stohlawetz P.J., Dzirlo L., Hergovich N., Lackner E., Mensik C., Eichler H.G., Kabrna E., Geissler K., and Jilma B. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95 (2000) 2983-2989
58. Tiwari A., Xu Z., and Hayward L.J. Aberrantly increased hydrophobicity shared by mutants of Cu,Zn-superoxide dismutase in familial amyotrophic lateral sclerosis. Journal of Biological Chemistry 280 (2005) 29771-29779
59. Traynor B.J., Bruijn L., Conwit R., Beal F., O'Neill G., Fagan S.C., and Cudkowicz M.E. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 67 (2006) 20-27
60. Veldink J.H., BarBär P.R., Joosten E.A.J., Otten M., Wokke J.H.J., and van den Berg L.H. Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. Neuromuscular Disorders 13 (2003) 737-743
61. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., and Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14 (1995) 1105-1116
62. Yang S.-H., Shi J., Day A.L., Simpkins J.W., and Robinson S.E. Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke 31 (2000) 745-750
63. Yang Y., Hentati A., Deng H., Dabbagh O., Sasaki T., Hirano M., Hung W., Ouahchi K., Yan J., Azim A., Cole N., Gascon G., Yagmour A., Ben-Hamida M., Pericak-Vance M., Hentati F., and Siddique T. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nature Genetics 29 (2001) 160-165